Was Dr. Bunn Insensitive Or Just Efficient? FDA Imbroglio Points To Larger Problems
In Brief: ASTRO Officers Named; AACR Fellowships Available; NRC Won’t Revoke NIH License
FDA Likely To Change Procedures For Patient Interaction, Official Says
RPR Grant To NABCO Does Not Support Advocacy, Firm Says
ODAC Chairman: Time Was Tight For Meeting
Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Cancer Center at Illinois is recognized as NCI Basic Cancer Center, becoming the first new institution to earn this designation in 40 years
- Most Favored Nation drug pricing could put China on top
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line









